Doctronic has raised $40 million in a Series B round co-led by Abstract and Lightspeed Venture Partners. Existing investors Union Square Ventures, Seven Stars, Mantis, and Tusk Ventures also joined the financing. The new round brings the company’s total funding to more than $65 million.

The raise comes less than a year after Doctronic’s earlier funding rounds and follows a period of rapid growth. Since closing its Series A, the company says it has grown 15x to 8 figure annualized revenue, nearly tripled its repeat patient rate, and reached more than 300,000 unique weekly visitors.

Why this matters in digital healthcare

The company is positioning itself in one of the most closely watched corners of healthcare AI: systems that move beyond answering questions and take part in actual care delivery. In December 2025, Doctronic said it became the first AI native platform to autonomously renew prescriptions under Utah’s AI Learning Lab regulatory sandbox.

That milestone matters because most AI health tools still stop at information or administrative support. Doctronic is making a different claim. It says its system can take responsibility for clinical outcomes in certain regulated settings, with physician oversight and escalation protocols in place for more complex situations.

“Doctronic proved what we believed from the start: AI can deliver better healthcare outcomes at scale. The Utah program validated their clinical rigor. The revenue growth validated market demand. What sets them apart is the courage to take responsibility for outcomes—not just provide information. That’s the future of healthcare.”

Ramtin Naimi, Partner at Abstract.

Where the new capital will go

Doctronic says the Series B funding will support a wider push into hospital systems, academic institutions, digital health platforms, and payers. The company also plans to expand into pediatrics, an area where it sees strong consumer demand and limited access to care.

“This round reflects Doctronic’s category leadership: unmatched consumer scale and a best-in-class AI clinical model. Health systems see us as infrastructure, the digital front door that routes their patients efficiently and keeps care in-network. Payers see us as unlimited primary care at predictable cost. This round lets us push further into academic medical centers, digital health platforms, and payers, while continuing to serve millions of consumers directly.”

Matt Pavelle, CEO, Co-founder of Doctronic.

The company is also in discussions with regulators in other states and with governments outside Utah as it looks to broaden its AI prescription services. That suggests Doctronic is trying to move from a single state proof point into a larger regulatory and commercial footprint.

The company behind the round

Doctronic was founded by Dr. Adam Oskowitz and Matt Pavelle. The New York based company says it built the first AI system trusted to make clinical decisions autonomously, operating through its own clinical practice licensed in all 50 states.

In Utah, the company launched prescription renewal services that let patients receive medication refills directly through AI without a physician intermediary. The program covers 190 medications and includes automatic 24/7 escalation to licensed physicians for more complex cases.

“We’re not just faster and cheaper than traditional care — we’re more thorough. Our AI performs dozens of safety checks per prescription renewal that would take a human physician an hour. The 99.2% treatment alignment rate isn’t theoretical, it’s from real patients in real clinical scenarios. But what I’m most proud of is retention. Since the Series A, monthly repeat physician visits have nearly tripled. Patients aren’t just trying us, they’re coming back.”

Dr. Oskowitz. Co-founder of Doctronic

Doctronic says its platform is HIPAA compliant and available around the clock. It also points to direct access to patient records screening through First Databank as part of the data infrastructure behind its system.

A crowded investor base and a fast funding pace

The Series B adds to a financing run that has moved quickly. This was Doctronic’s third round in less than 12 months, bringing in support from both new and returning backers as the company tries to widen its role across consumer and enterprise healthcare.

Alongside Abstract and Lightspeed Venture Partners, the round included Union Square Ventures, Seven Stars, Mantis, and Tusk Ventures. The mix reflects continued investor interest in healthcare AI companies that can show both regulatory progress and commercial traction.

Doctronic draws a sharp distinction between its model and general purpose AI assistants. Rather than stopping at health information, the company says its platform uses multiple specialized AI agents to conduct structured clinical reasoning under physician oversight. In settings where its AI is allowed to practice medicine more independently, including Utah, Doctronic says it also carries AI medical malpractice insurance.

Doctronic offers free AI consultations through its website and mobile apps, providing users with four potential diagnoses, treatment plans, and clinical documentation. Patients who want a physician visit can also access licensed providers 24/7 through video visits for an insurance copay or $39.

Origianl Creator: Paulo Palma
Original Link: https://justainews.com/companies/funding-news/doctronic-raises-40m-series-b-for-ai-healthcare/
Originally Posted: Tue, 24 Mar 2026 14:50:14 +0000